
    
      In this double-blind, placebo-controlled study, a total of 60 patients are randomized to
      receive PMPA prodrug at 1 of 5 doses or matching placebo tablets.

      Part A (Days 1-7): Patients receive a single dose of PMPA prodrug or matching placebo tablets
      administered orally followed by a 1-week observation period. Patients who complete Part A
      without a dose-limiting toxicity begin Part B.

      Part B (Days 8-35): Patients receive either PMPA prodrug or matching placebo tablets
      administered orally qd for 4 weeks at the same dosage level administered in Part A.
    
  